[1]顾益凤,朱自力,张金业,等.利用ROC曲线选择血清HE-4对卵巢癌的最佳诊断界点[J].现代检验医学杂志,2015,30(04):141-143.[doi:10.3969/j.issn.1671-7414.2015.04.043]
　GU Yi-feng,ZHU Zi-li,ZHANG Jin-ye,et al.Selecting the Best Cut-off Point of Serum HE-4 in Ovarian Cancer by ROC Curve[J].Journal of Modern Laboratory Medicine,2015,30(04):141-143.[doi:10.3969/j.issn.1671-7414.2015.04.043]
点击复制

利用ROC曲线选择血清HE-4对卵巢癌的最佳诊断界点()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第30卷
期数:
2015年04期
页码:
141-143
栏目:
检验与临床
出版日期:
2015-08-10

文章信息/Info

Title:
Selecting the Best Cut-off Point of Serum HE-4 in Ovarian Cancer by ROC Curve
文章编号:
1671-7414(2015)04-141-03
作者:
顾益凤; 朱自力; 张金业; 张小霞; 史跃燕
南通市肿瘤医院检验科,江苏南通 226361
Author(s):
GU Yi-feng; ZHU Zi-li; ZHANG Jin-ye; ZHANG Xiao-xia; SHI Yue-yan
Department of Clinical Laboratory,Nantong Tumor Hospital,Jiangsu Nantong 226361,China
关键词:
卵巢癌;  人附睾蛋白4(HE-4);  受试者工作特征曲线;  切割值
分类号:
R737.31; R730.43
DOI:
10.3969/j.issn.1671-7414.2015.04.043
文献标志码:
A
摘要:
目的 应用受试者工作特征曲线(ROC)确定血清人附睾蛋白4(HE-4)对卵巢癌的最佳诊断界点,为卵巢癌的早期诊断提供依据。方法 采用电化学发光免疫分析法(ECLIA)检测68例卵巢癌患者、42例卵巢良性肿瘤患者和30例健康妇女血清中HE-4的水平,绘制ROC曲线,运用统计软件分析。结果 血清HE-4水平在卵巢癌组、卵巢良性肿瘤组和健康对照组中均呈非正态分布。卵巢良性肿瘤组和健康组HE-4水平无显著差异,而卵巢癌组血清HE-4水平与卵巢良性肿瘤组、健康对照组两者差异均有统计学意义(P＜0.01)。血清HE-4值为108 pmol/L时,正确诊断指数(Youden's index)最大(0.713),敏感度和特异度分别为77.9%和93.1%,阳性预测值为91.4%,阴性预测值为81.7%,阳性似然比为11.6,阴性似然比为0.2,优势比(odds ratio)为47.3。结论 HE-4检测是卵巢癌诊断和排除诊断的较理想指标,选择108pmol/L作为卵巢癌诊断界点比较合适。
Abstract:
Objective Using ROC curve to determine the bestcut-off point of serum HE-4 in the diagnosis of ovarian cancer and provide important value to diagnosis early ovarian cancer.Methods The levels of serum HE-4 in 68 ovarian cancer patients,42 ovarian benign tumorpatients and 30 healthy female were detected by electrochemistry irradiance method.The ROC curve was drawn and the cut-off point of HE-4 was determined by statistical software.Results The levels of serum HE-4 were all non-normal distribution in the groups of ovarian cancer,ovarian benigntumor and healthy controls.Whats more,there was no significant difference between ovarian benign tumor group and normal control group.And compared with benign ovarian tumors and normal control group,the level of HE-4 in ovarian cancerswas significantly increased(P＜0.01).It would be best for diagnosis whenthe level of serum HE-4 was 108pmol/L in ovarian cancer.Youden's index showed the maximum(0.713)and the sensitivity and specificity of diagnosing were 77.9% and 93.1% respectively.The positive predictive value was 91.4% and negative predictive value was 91.4%.At the same time,the positive likelihood ratio was 11.6 and the negative likelihood ratio was 0.2,odds ratio reached to 47.3.Conclusion The detection of HE-4 is an ideal markfor diagnosing and excluding ovarian cancer.Selecting 108 pmol/L as ovarian cancer diagnosis point is relative appropriate.

参考文献/References:

[1] Li J,Dowdy S,Tipton T,et al.HE4 as a biomarker for ovarian and endometrial cancer management[J].Expert Revie Mol Diagn,2009,9(6):555-566.
[2] Moore RG,McMeekin DS,Brown AK,et al.A novel multiple marker bioassayutilizing HE4 and CA125 for the prediction of ovarian cancer in patients with apelvic mass[J].Gynecol Oncol,2009,112(1):40-46.
[3] 刘 磊,刘 彬,朱莉莉,等.肺鳞癌患者血清CYF RA21-1和SCC检测及ROC曲线和截断点的理论分析[J].中华肿瘤防治杂志,2012,19(4):280-283.
Liu L,Liu B,Zhu LL,et al.Clinical significance in squamous celllung cancer patients with serum CYFRA21-1 and SCC by ROC curve and cutoff theory[J].Chinese Journal of Cancer Prevention and Treatment,2012,19(4):280-283.
[4] Presl J,Kucerar R,TopolcanO,et al.HE4 a biomarker of ovariancancer[J].Ceska Gynekol,2012,77(5):445-449.
[5] Guan GF.Expression and clinical significance of OPN and HE4 gene proteinin epithelial ovarian cancer[J].J Med Forum,2009,30(10):9-13.
[6] Wang K,Gan L,Jeffrey E,et al.Monitoring gene expression profile changes in ovarian cancinoma using cDNA microarray[J].Gene,1999,229(1/2):101-108.
[7] Kǒbel M,Kalloger SE,Boyd N,et al.Ovarian carcinoma subtypes are different disease:implications for biomarker studies[J].PloS Med,2008,5(12):e232.
[8] Moore RG,Brown AK,Miller MC,et al.The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass[J].Gynecol Oncol,2008,108(2):402-408.
[9] 朱自力,戴伟萍,肖春红,等.血清HE4,CA125联合ROMA指数在卵巢癌预测和诊断中的应用价值[J].现代检验医学杂志,2014,29(2):76-77,80.
Zhu ZL,Dai WP,Xiao CH,et al.Value of combined assays of human epididymis protein 4,CA125 and ROMA index in patients with ovarian cancer[J].JMod Lab Med,2014,29(2):76-77,80.
[10] 苏 彤,王晓岩,刘 辉,等.联合检测附睾蛋白4和肿瘤抗原125在卵巢癌患者血清中的水平及临床意义[J].中国煤炭工业医学杂志,2011,14(10):1421-1423.
Su T,Wang XY,Liu H,et al.The value of the combined detection of serumHE4 and CA125 in the patients with varian carcinoma and their significance[J].Chinese Journal of Coal Industry Medicine,2011,14(10):1421-1423.
[11] 沈 嫱,宋光辉,张建兴.Logistic回归及ROC曲线综合评价超声造影对乳腺癌的诊断价值[J].实用医学杂志,2009,25(7):1058-1060.
Shen Q,Song GH,Zhang JX,et al.Comprehensive evaluation of the diagnostic value of contrast-enhanced sonography for breast cancer by ROC curve and logistic regression[J].The Journal of Practical Medicine,2009,25(7):1058-1060.
[12] Winarto H,Laihad BJ,Nuranna L.Modification of cu-toff values for HE4,CA125,the risk of malignancy index,and the risk of malignancy algorithm forovarian cancer detection in jakarta,indonesia[J].APJCP,2014,15(5):1949-1953.

相似文献/References:

[1]郑福利,张颖,王建.血清S100A6检测对卵巢上皮性癌的诊断价值[J].现代检验医学杂志,2015,30(05):22.[doi:10.3969/j.issn.1671-7414.2015.05.007]
　ZHENG Fu-li,ZHANG Ying,WANG Jian.Study on Diagnostic Value of Detecting Serum S100A6 in the Epithelial Ovarian Carcinoma[J].Journal of Modern Laboratory Medicine,2015,30(04):22.[doi:10.3969/j.issn.1671-7414.2015.05.007]
[2]詹颉,常宁宁,李小侠,等.CEA，AFP，CA125，CA199和CA72-4联合检测在鉴别卵巢良恶性疾病中的应用价值[J].现代检验医学杂志,2015,30(05):50.[doi:10.3969/j.issn.1671-7414.2015.05.015]
　ZHAN Jie,CHANG Ning-ning,LI Xiao-xia,et al.Clinical Value of Combined Detection of CEA，AFP，CA125，CA199 and CA72-4 in the Identification of Ovarian Benign and Malignant Disease[J].Journal of Modern Laboratory Medicine,2015,30(04):50.[doi:10.3969/j.issn.1671-7414.2015.05.015]
[3]邢瑞青,吴永昌,陈慧昱,等.血清CA125,HE4及ROMA指数对卵巢癌诊断价值的临床研究[J].现代检验医学杂志,2016,31(06):37.[doi:10.3969/j.issn.1671-7414.2016.06.010]
　XING Rui-qing,WU Yong-chang,CHEN Hui-yu,et al.Diagnostic Value of Serum CA125,HE4 and ROMA Index in Patients with Ovarian Cancer[J].Journal of Modern Laboratory Medicine,2016,31(04):37.[doi:10.3969/j.issn.1671-7414.2016.06.010]
[4]张 悦a,段海霞,暴 蕾a,等.microRNA-125b在葛根素诱导人卵巢癌细胞SKOV3凋亡中的作用研究[J].现代检验医学杂志,2017,32(05):13.[doi:10.3969/j.issn.1671-7414.2017.05.004]
　ZHANG Yuea,DUAN Hai-xia,BAO Leia,et al.Role of MicroRNA-125b in Human Ovarian Cancer Cell SKOV3 Induced Apoptosis by Puerarin[J].Journal of Modern Laboratory Medicine,2017,32(04):13.[doi:10.3969/j.issn.1671-7414.2017.05.004]
[5]徐金良a,杜丹丹,翟志敏,等.卵巢良恶性肿瘤患者血液NLR,LMR,RDW,PLR四项参数的变化及其临床意义[J].现代检验医学杂志,2018,33(02):16.[doi:10.3969/j.issn.1671-7414.2018.02.001]
　XU Jin-lianga,DU Dan-dan,ZHAI Zhi-min,et al.Changes and Clinical Significance of Four Parameters of NLR,LMR, RDW and PLR in Patients with Benign and Malignant Ovarian Tumors[J].Journal of Modern Laboratory Medicine,2018,33(04):16.[doi:10.3969/j.issn.1671-7414.2018.02.001]
[6]马同敏,赵志强.血清CA125,STIP1和IGF-Ⅰ联合检测对卵巢癌的早期诊断价值研究[J].现代检验医学杂志,2018,33(06):50.[doi:10.3969/j.issn.1671-7414.2018.06.013]
　MA Tong-min,ZHAO Zhi-qiang.Clinical Value of Combined Detection of Serum CA125,STIP1 and IGF-I Levels in Early Diagnosis of Ovarian Cancer[J].Journal of Modern Laboratory Medicine,2018,33(04):50.[doi:10.3969/j.issn.1671-7414.2018.06.013]
[7]张善弟,荆成宝,禹 梅.血清CEA,CA125和HE4联合检测对卵巢癌的诊断价值[J].现代检验医学杂志,2018,33(06):122.[doi:10.3969/j.issn.1671-7414.2018.06.032]
　ZHANG Shan-di,JING Cheng-bao,YU Mei.Clinical Value of Combined Detection of Serum CEA,CA125 and HE4 in the Diagnosis of Ovarian Cancer[J].Journal of Modern Laboratory Medicine,2018,33(04):122.[doi:10.3969/j.issn.1671-7414.2018.06.032]
[8]刘 青,邓慧敏,周林涛,等.卵巢癌患者组织中miR-135b的表达及临床意义[J].现代检验医学杂志,2019,34(02):32.[doi:10.3969/j.issn.1671-7414.2019.02.009]
　LIU Qing,DENG Hui-min,ZHOU Lin-tao,et al.Expression and Clinical Significance of miR-135bin Tissues of Patients with Ovarian Cancer[J].Journal of Modern Laboratory Medicine,2019,34(04):32.[doi:10.3969/j.issn.1671-7414.2019.02.009]
[9]侯 娟,蒋树立,滕长财.基于TCGA 数据库卵巢癌患者的miR-301b 表达量与生存状况生物信息学分析[J].现代检验医学杂志,2020,35(04):37.[doi:10.3969/j.issn.1671-7414.2020.04.009]
　HOU Juan,JIANG Shu-li,TENG Chang-cai.Bioinformatics Analysis of Mir-301b Expression and Survival Status of Patients with Ovarian Cancer Based on TCGA Database[J].Journal of Modern Laboratory Medicine,2020,35(04):37.[doi:10.3969/j.issn.1671-7414.2020.04.009]
[10]杨立芬,何建清,尹立新,等.人卵巢癌细胞SKOV3中壳多糖酶3样蛋白1的表达和对细胞增殖及侵袭的影响实验研究[J].现代检验医学杂志,2021,36(04):31.[doi:10.3969/j.issn.1671-7414.2021.04.007]
　YANG Li-fen,HE Jian-qing,YIN Li-xin,et al.Expression of Chitinase 3-like Protein 1 in Human Ovarian Cancer Cell Skov3and Its Effect on Cell Proliferation and Invasion[J].Journal of Modern Laboratory Medicine,2021,36(04):31.[doi:10.3969/j.issn.1671-7414.2021.04.007]

备注/Memo

备注/Memo:
作者简介:顾益凤(1974-),女,硕士学位,副主任技师,Tel:15252901521,E-mail:gyfkry@163.com。
更新日期/Last Update: 2015-08-10